Efficacy and Safety for the Use of Half-Dosed Pegylated Granulocyte Colony-Stimulating Factors in Preventing Febrile Neutropenia During Chemotherapy in Patients With Malignant Tumors: A Multicenter, Open-Labeled, Single-Arm Phase 2 Trial

BACKGROUND: Prophylactic granulocyte-colony stimulating factor (G-CSF) has been shown to effectively prevent febrile neutropenia (FN) and grade 3/4 neutropenia during myelosuppressive treatment. The present study reports the clinical efficacy and safety of the prophylactic use of G-CSF with a half d...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Qi, Li, Xiaoyu, Wang, Runkun, Qin, Kai, Cheng, Yi, Cheng, Weiting, Dong, Youhong, He, Zhen, Li, Jun, Li, Ming, Tang, Xi, Wang, Xudong, Xiao, Xuxuan, Yang, Bin, Zhou, Yajuan, Wang, Rui, Huang, Qiao, Hu, Guangyuan, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095430/
https://www.ncbi.nlm.nih.gov/pubmed/35574371
http://dx.doi.org/10.3389/fonc.2022.820324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095430/
https://www.ncbi.nlm.nih.gov/pubmed/35574371
http://dx.doi.org/10.3389/fonc.2022.820324

Ejemplares similares